| 臺大學術典藏 |
2018-09-10T15:21:53Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; YIH-LEONG CHANG |
| 臺大學術典藏 |
2018-09-10T15:23:10Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Jin-Tung Liang |
| 臺大學術典藏 |
2018-09-10T15:23:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
JAU-YU LIAU; Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H. |
| 臺大學術典藏 |
2018-09-10T15:25:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Ji-Shiang Hung |
| 臺大學術典藏 |
2020-03-07T06:56:23Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Yih-Leong Chang;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-06-16T07:53:31Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Liang-In Lin;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; LIANG-IN LIN; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-05T07:31:46Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Jia-Huei Tsai;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Yeh K.-H.; Cheng A.-L.; Chang Y.-L.; Lin L.-I.; Tseng L.-H.; JIA-HUEI TSAI; Liang J.-T.; Lin B.-R.; Hung J.-S. |
| 臺大學術典藏 |
2021-05-03T02:20:55Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Jin-Tung Liang;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-05-07T02:46:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
YI-HSIN LIANG; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG; Yeh K.-H. |
